715 related articles for article (PubMed ID: 21103660)
1. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Lindahl TL; Baghaei F; Blixter IF; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Hillarp A;
Thromb Haemost; 2011 Feb; 105(2):371-8. PubMed ID: 21103660
[TBL] [Abstract][Full Text] [Related]
2. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.
Van Blerk M; Bailleul E; Chatelain B; Demulder A; Devreese K; Douxfils J; Jochmans K; Mullier F; Wijns W; Soumali MR; Coucke W; Vernelen K; Van de Walle P
Thromb Haemost; 2015 Jan; 113(1):154-64. PubMed ID: 25231101
[TBL] [Abstract][Full Text] [Related]
3. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.
Hillarp A; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Lindahl TL
J Thromb Haemost; 2011 Jan; 9(1):133-9. PubMed ID: 20946166
[TBL] [Abstract][Full Text] [Related]
4. The effect of dabigatran on select specialty coagulation assays.
Adcock DM; Gosselin R; Kitchen S; Dwyre DM
Am J Clin Pathol; 2013 Jan; 139(1):102-9. PubMed ID: 23270905
[TBL] [Abstract][Full Text] [Related]
5. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
Hapgood G; Butler J; Malan E; Chunilal S; Tran H
Thromb Haemost; 2013 Aug; 110(2):308-15. PubMed ID: 23783268
[TBL] [Abstract][Full Text] [Related]
6. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Hawes EM; Deal AM; Funk-Adcock D; Gosselin R; Jeanneret C; Cook AM; Taylor JM; Whinna HC; Winkler AM; Moll S
J Thromb Haemost; 2013 Aug; 11(8):1493-502. PubMed ID: 23718677
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
[TBL] [Abstract][Full Text] [Related]
8. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample.
Mattsson C; Menschiek-Lundin A; Wåhlander K; Lindahl TL
Thromb Haemost; 2001 Aug; 86(2):611-5. PubMed ID: 11522011
[TBL] [Abstract][Full Text] [Related]
9. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban.
Gosselin RC; Adcock D; Hawes EM; Francart SJ; Grant RP; Moll S
Thromb Haemost; 2015 Jan; 113(1):77-84. PubMed ID: 25413383
[TBL] [Abstract][Full Text] [Related]
11. Pitfalls in the assessment of disseminated intravascular coagulation in patients on dabigatran.
Kanda GS; Ho WK; Rodrigues C; Bousounis A; Hogan C
Pathology; 2021 Aug; 53(5):623-627. PubMed ID: 33526243
[TBL] [Abstract][Full Text] [Related]
12. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study.
Dager WE; Gosselin RC; Kitchen S; Dwyre D
Ann Pharmacother; 2012 Dec; 46(12):1627-36. PubMed ID: 23232017
[TBL] [Abstract][Full Text] [Related]
13. Effects of telavancin on coagulation test results.
Barriere SL; Goldberg MR; Janc JW; Higgins DL; Macy PA; Adcock DM
Int J Clin Pract; 2011 Jul; 65(7):784-9. PubMed ID: 21564449
[TBL] [Abstract][Full Text] [Related]
14. Dabigatran assessment in patients with acute complications using routine coagulation assays.
Stang L; Nahirniak S; Butcher K; Szkotak AJ
Blood Coagul Fibrinolysis; 2014 Jul; 25(5):426-34. PubMed ID: 24637695
[TBL] [Abstract][Full Text] [Related]
15. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
[TBL] [Abstract][Full Text] [Related]
16. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
[TBL] [Abstract][Full Text] [Related]
17. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
Mani H; Herth N; Kasper A; Wendt T; Schuettfort G; Weil Y; Pfeilschifter W; Linnemann B; Herrmann E; Lindhoff-Last E
Ther Drug Monit; 2014 Oct; 36(5):624-31. PubMed ID: 24577124
[TBL] [Abstract][Full Text] [Related]
18. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate.
Dinkelaar J; Patiwael S; Harenberg J; Leyte A; Brinkman HJ
Clin Chem Lab Med; 2014 Nov; 52(11):1615-23. PubMed ID: 24902009
[TBL] [Abstract][Full Text] [Related]
19. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
Thromb Haemost; 2007 Jul; 98(1):155-62. PubMed ID: 17598008
[TBL] [Abstract][Full Text] [Related]
20. From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples.
Helin TA; Lemponen M; Hjemdahl P; Rönquist-Nii Y; Lassila R; Joutsi-Korhonen L
Thromb Res; 2015 Jul; 136(1):154-60. PubMed ID: 25981140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
